H Tilg|A Kaser - JoVE Visualize

Showing results (81-90 of 130) with videos related to

Pageof 13

Sort By:

Transplantation|April 1, 1992

Urinary and pancreatic juice neopterin excretion after combined pancreas-kidney transplantationH Tilg, A Königsrainer, R Krausler, et al.

Annals of Hematology|February 1, 1991

Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2W E Aulitzky, H Tilg, W Vogel, et al.

Cytokine|March 1, 1994

Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humansH Tilg, E Trehu, L Shapiro, et al.

Oncogene|February 17, 2009

Cooperation between GLI and JUN enhances transcription of JUN and selected GLI target genesS Laner-Plamberger, A Kaser, M Paulischta, et al.

International Journal of Sports Medicine|December 2, 2005

The impact of prolonged strenuous endurance exercise on interleukin 18 and interleukin 18 binding protein in recreational cyclistsG Neumayr, O Ludwiczek, H Hoertnagl, et al.

Clinical and Experimental Immunology|November 1, 1991

Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma)W E Aulitzky, H Grosse-Wilde, U Westhoff, et al.

Transplantation|July 1, 1992

Circulating serum levels of interleukin 6 and C-reactive protein after liver transplantationH Tilg, J Nordberg, W Vogel, et al.

Transplantation|October 1, 1990

Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messagesD Niederwieser, M Herold, W Woloszczuk, et al.

Journal of Immunology (Baltimore, Md. : 1950)|August 15, 1994

Biologic activity of low dosage IL-2 treatment in vivo. Molecular assessment of cytokine network interactionF Hladik, J A Tratkiewicz, H Tilg, et al.

Acta Medica Austriaca|January 1, 1985

[Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon]W Aulitzky, G Gastl, J Troppmair, et al.

Pageof 13

Showing results (81-90 of 130) with videos related to

Sort By:

Pageof 13

Transplantation|April 1, 1992

Urinary and pancreatic juice neopterin excretion after combined pancreas-kidney transplantationH Tilg, A Königsrainer, R Krausler, et al.

Annals of Hematology|February 1, 1991

Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2W E Aulitzky, H Tilg, W Vogel, et al.

Cytokine|March 1, 1994

Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humansH Tilg, E Trehu, L Shapiro, et al.

Oncogene|February 17, 2009

Cooperation between GLI and JUN enhances transcription of JUN and selected GLI target genesS Laner-Plamberger, A Kaser, M Paulischta, et al.

International Journal of Sports Medicine|December 2, 2005

The impact of prolonged strenuous endurance exercise on interleukin 18 and interleukin 18 binding protein in recreational cyclistsG Neumayr, O Ludwiczek, H Hoertnagl, et al.

Clinical and Experimental Immunology|November 1, 1991

Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma)W E Aulitzky, H Grosse-Wilde, U Westhoff, et al.

Transplantation|July 1, 1992

Circulating serum levels of interleukin 6 and C-reactive protein after liver transplantationH Tilg, J Nordberg, W Vogel, et al.

Transplantation|October 1, 1990

Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messagesD Niederwieser, M Herold, W Woloszczuk, et al.

Journal of Immunology (Baltimore, Md. : 1950)|August 15, 1994

Biologic activity of low dosage IL-2 treatment in vivo. Molecular assessment of cytokine network interactionF Hladik, J A Tratkiewicz, H Tilg, et al.

Acta Medica Austriaca|January 1, 1985

[Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon]W Aulitzky, G Gastl, J Troppmair, et al.

Pageof 13